Centro Medico Teknon-Grupo Quironsalud
- Address
- lock Available on a paid plan
Digestive System Diseases
The Sleep Unit at Centro Medico Teknon-Grupo Quironsalud is investigating Crohn's disease, focusing on the safety and tolerability of a novel subcutaneous therapy.
- Safety profiling of RO7790121 in moderate to severe Crohn’s disease
- Evaluation of patient‑reported outcomes
- Integration of endoscopic biomarkers
Three active trials involve ten investigators, advancing therapeutic options for digestive disorders.
Female Urogenital Diseases and Pregnancy Complications
Researchers are studying sleep disturbances associated with menopause and testing the efficacy of the new compound elinzanetant using polysomnography.
- Efficacy of elinzanetant on sleep architecture
- Safety monitoring in post‑menopausal women
- Quality‑of‑life assessments
The goal is to expand safe treatment choices for women experiencing menopausal sleep problems.
Nutritional and Metabolic Diseases
The site’s program includes research on obesity, evaluating the cardiovascular safety of the investigational agent BI 456906 in overweight participants.
- Cardiovascular event monitoring
- Metabolic parameter analysis
- Long‑term weight change evaluation
Findings will inform whether this therapy offers a safer approach to weight management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Medico Teknon-Grupo Quironsalud
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants with Moderate-to-Severe Active Ulcerative Colitis. | Xencor Inc. | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obefazimod | 5 | Unknown | 2021-12-01 | 2025-01-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.